EP3761995A1 - Beta-glucane aus hefe - Google Patents

Beta-glucane aus hefe

Info

Publication number
EP3761995A1
EP3761995A1 EP19709893.2A EP19709893A EP3761995A1 EP 3761995 A1 EP3761995 A1 EP 3761995A1 EP 19709893 A EP19709893 A EP 19709893A EP 3761995 A1 EP3761995 A1 EP 3761995A1
Authority
EP
European Patent Office
Prior art keywords
patient
yeast beta
yeast
present
colon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19709893.2A
Other languages
English (en)
French (fr)
Inventor
Marco Alexander Van Den Berg
Emanuel Enzo CANFORA
Ellen Elisabeth BLAAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Maastricht
Universiteit Maastricht
DSM IP Assets BV
Original Assignee
University Maastricht
Universiteit Maastricht
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Maastricht, Universiteit Maastricht, DSM IP Assets BV filed Critical University Maastricht
Publication of EP3761995A1 publication Critical patent/EP3761995A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to yeast beta glucans for increasing the acetate concentration in the colon of a patient.
  • the present invention relates to yeast beta glucans for use in a method of treating or preventing a condition selected from overweight and obesity in a human or animal patient in need thereof.
  • the present invention relates to an alimentary product, or a food supplement, comprising yeast beta glucan and/or starch.
  • the present invention relates to a method for increasing the acetate concentration in the colon of a patient.
  • the incidence of obesity is growing rapidly and obesity has become a major health care problem of the 21st century.
  • Adipose tissue, skeletal muscle and the liver are major organs involved in substrate metabolism and research over the past decade revealed the presence of a strong inter-organ relationship in substrate metabolism. Therefore, functional disturbances in either of these organs can theoretically cause or contribute to the development of insulin resistance.
  • the obese insulin resistant state is characterized by adipose tissue dysfunction, resulting in systemic lipid overflow and ectopic lipid accumulation in liver and skeletal muscle.
  • skeletal muscle exhibits an impaired mitochondrial function and an impaired ability to adjust lipid oxidation to lipid supply. This leads to the accumulation, altered composition and/or localization of bioactive lipid metabolites interfering with insulin action.
  • the gut microbiota is increasingly being recognized as an important factor in fat distribution, insulin sensitivity and glucose and lipid metabolism. Accordingly, the intestinal microbiota could play an important role in the development of obesity and diabetes.
  • One of the important functions of the human microbiota is the fermentation of indigestible carbohydrates, i.e. dietary fiber or resistant starches.
  • the major products of this fermentation process are short-chain fatty acids (SCFA).
  • SCFA supplementation prevented diet-induced obesity and insulin resistance.
  • increasing the acetate availability prevents diet-induced body weight gain, counteracts adiposity, and improves glucose homeostasis and insulin sensitivity.
  • yeast beta-glucans (YBG), or yeast b-glucans, is defined herein as b-D-glucose polysaccharides containing a b-I ,b-O ⁇ Iiiooeb backbone with b-I ,q-D-glucose branches which are derived from yeast cell walls.
  • Resistant starch as used herein, is defined as "the sum of starch and products of starch degradation not absorbed in the small intestine of healthy individuals" (Euresta Newsletter 1 1 .1 (1991 ). Those of ordinary skill in the art generally classify resistant starch into one of the following four different classifications: RS1 , RS2, RS3, or RS4 as defined in Brown, McNaught and Moloney (1995) Food Australia 47: 272-275.
  • RS1 refers to starch that is physically inaccessible that is locked within cell walls of botanical substances and therefore qualifies as resistant starch.
  • the RS1 type of resistant starch is, for example, found in partially milled grains, seeds, and legumes.
  • RS2 refers to native resistant starch which are a component of starch granules such as those found in bananas (especially green bananas) and raw potatoes. Bananas and raw potatoes have relatively low gelatinization temperatures, typically on the order of about 60° C to about 80° C, which often presents substantial problems in the formulation of food products. Intragranular polymeric rearrangements that lead to an increased granular resistance to amylase digestion are also included in this category. This increased resistance could be the result of heat and/or moisture treatments or annealing of the intact granule.
  • RS3 refers to retrograded non-granular starch or crystalline non-granular starch, such as starch found in cooked and cooled potatoes, bread crusts, and cereals (cornflakes, for example) and starch pastes that have been extensively processed (by repeated cooking and cooling).
  • RS4 refers to specific starches that have been chemically modified and/or re-polymerized (which may include molecular weight reduction), such as ethers, esters, and crossbonded starches, as well as chain linkage altered dextrins, pyrodextrins, and maltodextrins.
  • Overweight is defined herein as a medical condition wherein the individual has a BMI of 25 to 30 kg/m 2 .
  • Obesity is defined herein as a medical condition wherein the individual has a BMI of higher than 30 kg/m 2 .
  • patient refers to an animal or human that is treatable by the present invention.
  • patient refers to both the male and female gender unless one gender is specifically indicated.
  • present patient can be mentioned a subject.
  • treatment in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder.
  • prevention in relation to a given disease or disorder means preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • alimentary product refers to products intended for oral consumption by a mammal, typically a human, to provide sustenance and/or satisfy nutritional requirements.
  • the present invention relates to beta glucans for increasing the acetate concentration in the distal colon of a human or animal patient, comprising a step of orally administering an effective amount of the yeast beta glucan to a human or animal patient in need thereof.
  • the beta glucans are yeast beta glucans. It was surprisingly found by the present inventors that addition of yeast beta glucans increases the acetate concentration in the colon of a patient, particularly in the distal colon. This is beneficial for inhibiting body weight gain or reducing body weight. Accordingly, in a preferred embodiment, the present invention relates to yeast beta glucans for use as a dietary supplement.
  • the present invention relates to yeast beta glucans for use as a medicament. More preferably, the present invention relates to yeast beta glucans for use in a method of treating or preventing overweight, or to yeast beta glucans for use in a method of treating or preventing obesity. It is advantageous that the yeast beta glucans are bioavailable in the distal colon, even after passing the gastrointestinal tract after oral intake of the yeast beta glucans. Accordingly, in a preferred embodiment the yeast beta glucans are taken orally.
  • the present yeast beta glucans for increasing the acetate concentration in the colon of a human or animal patient, or for use in a method of treating or preventing a condition selected from overweight and obesity in a human or animal patient in need thereof comprises the step of administering an effective amount of a yeast beta glucan to the human or animal patient in need thereof.
  • the present patient is suffering from overweight and/or obesity.
  • the obesity is prevalent obesity.
  • the obesity is prevalent abdominal obesity.
  • the obesity is new-onset obesity.
  • the present patient is suffering from insufficient acetate concentration in the colon, more preferably in the distal colon.
  • the present patient is in a further embodiment suffering from conditions chosen from the group of reducing complications associated with obesity including vascular disease, such as coronary artery disease, stroke, peripheral vascular disease, ischemia reperfusion, etc.; hypertension; onset and/or progression of diabetes type II; hyperlipidemia, glucose homeostasis, gastrointestinal / digestivce discomfort, irritable bowel syndrome, systemic low grade inflammation and musculoskeletal diseases.
  • vascular disease such as coronary artery disease, stroke, peripheral vascular disease, ischemia reperfusion, etc.
  • hypertension onset and/or progression of diabetes type II
  • hyperlipidemia glucose homeostasis
  • gastrointestinal / digestivce discomfort irritable bowel syndrome
  • systemic low grade inflammation and musculoskeletal diseases.
  • the present condition is a hyperglycemic medical condition.
  • the hyperglycemic medical condition is diabetes, diabetes mellitus type I, diabetes mellitus type II, or gestational diabetes, either insulin-dependent or non-insulin-dependent.
  • the invention treats the hyperglycemic medical condition by reducing one or more complications of diabetes including nephropathy, retinopathy and vascular disease. The present invention, in various embodiments, accordingly provides methods of treating or preventing these complications.
  • the present condition or pathology is metabolic syndrome.
  • Metabolic Syndrome also known as metabolic syndrome X, insulin resistance syndrome or Reaven's syndrome, is typically characterized by a clustering of at least three or more of the following risk factors: (1 ) abdominal obesity (excessive fat tissue in and around the abdomen), (2) atherogenic dyslipidemia (blood fat disorders including high triglycerides, low HDL cholesterol and high LDL cholesterol that enhance the accumulation of plaque in the artery walls), (3) elevated blood pressure, (4) insulin resistance or glucose intolerance, (5) prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor-1 in blood), and (6) pro-inflammatory state (e.g., elevated C-reactive protein in blood).
  • prothrombotic state e.g., high fibrinogen or plasminogen activator inhibitor-1 in blood
  • pro-inflammatory state e.g., elevated C-reactive protein in blood.
  • Metabolic Syndrome (a) abdominal obesity (a waist circumference over 102 cm in men and over 88 cm in women); (b) serum triglycerides (150 mg/dl or above); (c) HDL cholesterol (40 mg/dl or lower in men and 50 mg/dl or lower in women); (d) blood pressure (130/85 or more); and (e) fasting blood glucose (1 10 mg/dl or above).
  • an individual having high insulin levels (an elevated fasting blood glucose or an elevated post meal glucose alone) with at least two of the following criteria meets the criteria for Metabolic Syndrome: (a) abdominal obesity (waist to hip ratio of greater than 0.9, a body mass index of at least 30 kg/m2, or a waist measurement over 37 inches); (b) cholesterol panel showing a triglyceride level of at least 150 mg/dl or an HDL cholesterol lower than 35 mg/dl; (c) blood pressure of 140/90 or more, or on treatment for high blood pressure.
  • abdominal obesity waist to hip ratio of greater than 0.9, a body mass index of at least 30 kg/m2, or a waist measurement over 37 inches
  • cholesterol panel showing a triglyceride level of at least 150 mg/dl or an HDL cholesterol lower than 35 mg/dl
  • blood pressure 140/90 or more, or on treatment for high blood pressure.
  • the present patient is aged 15 years or older, 20 years or older, 25 years or older or 30 years or older, e.g. a patient aged from 30 to 65 years. It was found by the present inventors that the patients suffering from overweight and/or obesity benefit from the intake of yeast beta glucans. More particularly, the present patient is man. More preferably the present patient is a pre-diabetic man. Pre-diabetic man are characterized in that they suffer from plasma glucose levels from 5.6 to 7.0 mmol/L or from 6.1 to 7.0 mmol/L.
  • the patient has a body mass index (BMI) of 25 or more, e.g. 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more or 40 or more.
  • BMI body mass index
  • the patient is an adult male, typically a male of over 18 years of age, having a body mass index (BMI) of 25 or more, e.g. 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more or 40 or more.
  • BMI body mass index
  • the patient is an adult female, typically a female of over 18 years of age, having a body mass index (BMI) of 25 or more, e.g. 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more or 40 or more.
  • BMI body mass index
  • the patient is a juvenile or adolescent male or female, typically a male or female of under 18 years of age, having a body mass index (BMI) of 25 or more, e.g. 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more or 40 or more.
  • BMI body mass index
  • the present patient is suffering from impaired fasting glucose, meaning that the patient 's plasma glucose levels during fasting are consistently above the normal range, but below the diagnostic cut-off for a formal diagnosis of diabetes mellitus.
  • the present patient has a plasma glucose level during fasting within the range of 5.5-7.0 mmol/L, preferably within the range of 5.75-7.0 mmol/L, more preferably 6.1-7.0 mmol/L.
  • the present patient has a plasma glucose of from 6.1 to 7.0 mmol/L.
  • the present patient has an impaired glucose tolerance.
  • impaired glucose tolerance is defined as two-hour glucose levels 7.8 to 1 1.0 mmol/L on the 75-g oral glucose tolerance test.
  • a patient is said to be under the condition of IGT when he/she has an intermediately raised glucose level after 2 hours, but less than the level that would qualify for type 2 diabetes mellitus.
  • the patient has an impaired glucose tolerance, as evidenced by a plasma glucose level within the range of 7.0 to 1 1 .0 mmol/L on the 75-g oral glucose tolerance test, more preferably a plasma glucose level within the range of 7.8 to 1 1.0 mmol/L on the 75-g oral glucose tolerance test.
  • the present patient has a plasma glucose of from 7.0 mmol/L to 1 1.0 mmol/L or 7.8 to 1 1 .0 mmol/L, preferably the present patient has a plasma glucose of from 7.0 mmol/L to 1 1.0 mmol/L on the 75-g oral glucose tolerance test or 7.8 to 1 1.0 mmol/L on the 75-g oral glucose tolerance test.
  • the invention maybe used to improve digestive health or comfort in healthy subjects or healthy patients, such as reduce flatulence, wind, intestinal bloating, distention of the abdomen by gas, pain or abdominal cramps, rumbling, reduce sensitivity to inulin, or improve stool frequency or stool consistency or bowel function.
  • the patient may have a digestive condition such as Functional gastrointestinal disorders (FGIDs) which are diagnosed and classified using the Rome IV criteria (released in May 2016; Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE and The Rome IV Committees.
  • FGIDs Functional gastrointestinal disorders
  • functional bowel disorders such as functional diarrhea, functional constipation, Irritable Bowel Syndrome IBS with predominant diarrhea [IBS-D], IBS with predominant constipation [IBS-C], and IBS with mixed bowel habits.
  • the methods as described herein comprise the step of identifying a patient that is in need of receiving treatment with the compositions of the invention and/or identifying a patient suffering from or at risk of suffering from any of the conditions as described here above and/or a subject meeting any of the above-described physiological characteristics as described here above.
  • the present patient has a systolic blood pressure of 100- 140mmHg and diastolic blood pressure of 60-90 mmHg.
  • the present colon is the distal colon.
  • the inventors found that yeast beta glucans are bioavailable in the distal colon. Accordingly, in a preferred embodiment the present yeast beta glucans are for improving the bioavailability of yeast beta glucans in the distal colon of the present patient.
  • the present effective amount is effective to increase the acetate concentration of the patient’s colon, preferably the distal colon. More preferably, the present effective amount of yeast beta glucan is a daily amount of at least 0.01 g, at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g or at least 10 g.
  • the present effective amount is a daily amount of yeast beta glucan of less than 25 g, less than 20 g, less than 15 g, less than 12.5 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g, less than 6 g or less than 5 g.
  • the present effective amount of yeast beta glucan is a daily amount within the range of 0.01 to 25 gam, 1 to 20 gram, 2.5 to 15 gram, 5 to 12.5 gram, 6 to 10 gram or 7 to 9 gram.
  • the present yeast beta glucans are dosed three times a day, more preferably the present yeast beta glucans are dosed as a supplement to breakfast, lunch and dinner. More preferably, the present yeast beta glucans are dosed during a time period of at least 14 days.
  • the treatment as defined herein is continued for a period of at least two weeks, preferably at least 3 weeks, at least 4 weeks, at least 1 month, at least two months, at least three months, at least 4 months, at least 5 months, or at least 6 months.
  • the present invention comprises a step of diagnosing a patient with insufficient acetate concentration in the colon, preferably in the distal colon. More preferably, the present invention comprises a step of diagnosing a patient as overweight or obese. More preferably the present invention comprises diagnosing a patient as having a condition as mentioned above.
  • the present yeast beta glucans are derived from a yeast of the genera Cyberlindnera, Candida, Yarowia, Pichia, Saccharomyces. More preferably the yeast is of the species Cyberlindnera jadinii, Yarowia lipolytica, Pichia pastoris, Candida utilis, Saccharomyces cerevisiae or Saccharomyces boulardii. Even more preferably the yeast is of the species Saccharomyces cerevisiae or Saccharomyces boulardii.
  • the present yeast beta glucans are in spray dried form.
  • the present yeast beta glucans are suitable to be dosed orally, for example as a supplement in a meal.
  • a spray dried form is advantageous in view of easy handling of the yeast beta glucans, as well as storability.
  • the present invention further comprises a step of administering an effective amount of starch, or resistant starch, to a human or animal patient in need thereof.
  • an effective amount of starch, or resistant starch to a human or animal patient in need thereof.
  • the inventors found that co-administering a starch, or a resistant starch, with the present yeast beta glucans, or present yeast cell walls, further increases the acetate concentration in the colon of the present patient.
  • the present starch is potato starch.
  • the present starch is wheat, maize, rice or cassava starch.
  • the present effective amount of starch is an amount which is sufficient to increase the concentration of acetate in the colon of a patient.
  • an amount which is sufficient to increase the concentration of acetate in the colon of a patient in comparison with the addition of yeast beta glucans to the patient without administering starch is a daily amount within the range of 0.01 to 25 gam, 1 to 20 gram, 2.5 to 15 gram, 5 to 12.5 gram, 6 to 10 gram or 7 to 9 gram.
  • the daily amount of starch is at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g or at least 10 g.
  • the unit dose amount of the resistant starch is less than 25 g, less than 20 g, less than 15 g, less than 12.5 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g, less than 6 g or less than 5 g.
  • the yeast beta glucans may be combined with Resistant Starch.
  • Resistant starch occurs naturally in a form physically inaccessible to a-amylase (RS1 ), or as native starch that can be made accessible to the enzyme by gelatinisation (RS2), or as retrograded starch formed through a cooking and cooling process (RS3) and finally as a chemically modified starch (RS4).
  • RS2, RS3 and RS4 are not digested by mammalian intestinal enzymes and are partly fermented in the colon and these three types are classified as Functional Fibre.
  • Examples of commercially available resistant starch are, but not limited to, derived from corn (HI-MAIZE® 260; Ingredion, Westchester, USA), granular potato starch (AVEBE, The Netherlands), from tapioca (C* Actistar 1 1700; Cerestar, France).
  • the yeast beta glucans and the resistant starch are administered orally in the form of a single composition or, alternatively are administered simultaneously or consecutively.
  • the time in between the administration of the respective components is less than 5 hours, preferably less than 4 hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 30 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes or less than 5 minutes.
  • the present yeast beta glucans have a size larger than 0.3 kDa, preferably larger than 0.8 kDa, more preferably larger than 3 kDa, more preferably larger than 5 kDa, even more preferably larger than 10 kDa, even more preferably larger than 20 kDa, even more preferably larger than 30 kDa, even more preferably larger than 50 kDa, even more preferably larger than 100 kDa, even more preferably larger than 200 kDa, even more preferably larger than 500 kDa.
  • the present yeast beta glucans have a size of 0.3 to 20000 kDa, preferably a size of 0.8 to 20000 kDa, more preferably a size of 3 to 20000 kDa, or 5 to 20000 kDa, or 10 to 20000 kDa, or 20 to 20000 kDa, or 30 to 20000 kDa, or 50 to 20000 kDa.
  • the present glucan fragments have a length of 0.3 to 50 kDa.
  • the present yeast beta glucans comprise 8-1 ,3-glucan fragments and/or b-I ,q-glucan fragments.
  • the ratio b-I ,q-glucan fragments to 8-1 ,3-glucan fragments is between 1 :20 to 1 :2, like 1 :20 to 1 :3, like 1 :20 to 1 :4, like 1 :20 to 1 :5, or 1 :20 to 1 :10, or 1 : 10 to 1 :5, like 1 :10 to 1 :4, like 1 : 10 to 1 :3, or 1 : 10 to 1 :2.
  • the present yeast beta glucans are in the form of yeast cell walls.
  • the present invention relates to yeast cell walls for increasing the acetate concentration in the colon of a patient.
  • the present invention relates to yeast cell walls for use in a method of treating or preventing a condition selected from overweight and obesity in a human or animal patient in need thereof More preferably, the present yeast cell walls are in spray dried form.
  • the present yeast cell walls are derived from yeast.
  • the yeast cell walls are derived from yeast cell walls by treating yeast cells to provide disrupted yeast cell walls and separating the disrupted yeast cell walls.
  • the present yeast cell walls are disrupted yeast cell walls.
  • the present yeast cell walls are not attached to a viable or reproducible yeast cell. Treating yeast cells to provide disrupted yeast cell walls may be carried out with standard techniques known in the art, like an enzymatic process with proteases and/or a physical process with milling or grinding.
  • the concentration of b-glucan in the present yeast cell walls is increased by treating the disrupted yeast cell walls with standard techniques known in the art, like an enzymatic process, like pH treatments, like chromatographic purification steps, and/or physical processes like centrifugation.
  • the b-glucan concentration in the yeast cell walls is between 5% (w/w) and 100% (w/w), such as between 10% (w/w) and 50% (w/w), or between 15% (w/w) and 50% (w/w), or between 20% (w/w) and 40% (w/w), or between 20% (w/w) and 25% (w/w) or between 40% (w/w) and 50% (w/w), or between 50% (w/w) and 100% (w/w).
  • the yeast cell walls are in spray dried form.
  • the yeast cell walls are suitable to be dosed orally, for example as a supplement in a meal.
  • a spray dried form is advantageous in view of easy handling of the yeast cell walls, as well as storability.
  • the present yeast cell walls are provided in the form of particles in a size range between 0.1 and 1000 micrometer, like between 0.1 and 10 micrometer, or between 0.5 and 20 micrometer, or between 1 and 10 micrometer, or between 1 and 100 micrometer, or between 10 and 200 micrometer, or between 10 and 1000.
  • the yeast cell walls can be obtained from any food grade yeast.
  • the yeast is of the genera Cyberlindnera, Candida, Yarowia, Pichia, Saccharomyces. More preferably the yeast is of the species Cyberlindnera jadinii, Yarowia lipolytica, Pichia pastoris, Candida utilis, Saccharomyces cerevisiae or Saccharomyces boulardii. Even more preferably the yeast is of the species Saccharomyces cerevisiae or Saccharomyces boulardii.
  • the yeast cell walls may comprise proteins.
  • the proteins may be in the range of 0-70% (w/w), like 1-50% (w/w), 5-40% (w/w), 10-30% (w/w), 10-45% (w/w), 10-40% (w/w), 15-35% (w/w), 20-30% (w/w).
  • the yeast cell walls may comprise lipids.
  • the amount of lipids may be in the range of 0-50% (w/w), like 1-40% (w/w), 4-30% (w/w), 5-25% (w/w), 6-20% (w/w), 7-15% (w/w) or 10-20% (w/w).
  • the lipids may be, but not limited to, in the form of monoglycerides, diglycerides, triglycerides, or phospholipids.
  • the fatty acid components of the lipids comprises both saturated fatty acids and unsaturated fatty acids.
  • the present yeast cell walls comprise mannans. More preferably, the present yeast cell walls comprise 1 to 50% (w/w) mannans, more preferably 5 to 40% (w/w) mannans, most preferably 10 to 30% (w/w) mannans.
  • the present yeast cell walls comprise:
  • the present yeast cell walls are dosed in a daily amount of at least 0.01 g, at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g, at least 10 g, at least 15 g, at least 20 g, at least 25 g or at least 30 g.
  • the present yeast cell walls are dosed in a daily amount of less than 60 g, less than 50 g, less than 45 g, less than 40 g, less than 39 g, less than 38 g, less than 37 g, or less than 36.
  • the present effective amount of yeast beta glucan is a daily amount within the range of 0.01 to 100 gam, 10 to 50 gram, 20 to 45 gram or 25 to 40 gram.
  • the present yeast beta glucans are in the form of a composition comprising the present yeast beta glucans.
  • the present invention relates to a composition comprising the present yeast beta glucans for increasing the acetate concentration in the colon of a patient.
  • the present invention relates to a composition comprising the present yeast beta glucans for a method of treating or preventing a condition selected from overweight and obesity in a human or animal patient in need thereof More preferably, the present composition comprising the present yeast beta glucans is in spray dried form.
  • the b-glucan concentration in the present composition comprising yeast beta glucans is between 5% (w/w) and 100% (w/w), such as between 10% (w/w) and 50% (w/w), or between 15% (w/w) and 50% (w/w), or between 20% (w/w) and 40% (w/w), or between 20% (w/w) and 25% (w/w) or between 40% (w/w) and 50% (w/w), or between 50% (w/w) and 100% (w/w).
  • the present composition comprising yeast beta glucans are in the form of particles in a size range between 0.1 and 1000 micrometer, like between 0.1 and 10 micrometer, or between 0.5 and 20 micrometer, or between 1 and 10 micrometer, or between 1 and 100 micrometer, or between 10 and 200 micrometer, or between 10 and 1000.
  • the present composition comprising yeast beta glucans may comprise proteins.
  • the proteins may be in the range of 0-70% (w/w), like 1-50% (w/w), 5-40% (w/w), 10-30% (w/w), 10-45% (w/w), 10-40% (w/w), 15-35% (w/w), 20-30% (w/w).
  • the present composition comprising yeast beta glucans may comprise lipids.
  • the amount of lipids may be in the range of 0-50% (w/w), like 1-40% (w/w), 4-30% (w/w), 5-25% (w/w), 6-20% (w/w), 7-15% (w/w) or 10-20% (w/w).
  • the lipids may be, but not limited to, in the form of monoglycerides, diglycerides, triglycerides, or phospholipids.
  • the fatty acid components of the lipids comprises both saturated fatty acids and unsaturated fatty acids.
  • the present composition comprising yeast beta glucans comprises mannans. More preferably, the present composition comprising yeast beta glucans comprise 1 to 50% (w/w) mannans, more preferably 5 to 40% (w/w) mannans, most preferably 10 to 30% (w/w) mannans.
  • the present composition comprising yeast beta glucans comprises:
  • the present invention relates to an alimentary product, or a food supplement, comprising the present yeast beta glucans, the present starch, the present yeast cell walls and/or the present composition comprising yeast beta glucans.
  • the alimentary product is a liquid, semi-solid or solid composition suitable for oral consumption by a mammal, typically a human, either in the form in which it is presented or after further processing, such as the addition of one more further edible components.
  • This alimentary product is preferably a food composition, a food product, a dietetic food product, a nutraceutical, a functional food product, a medical food product, a food additive, a food supplement, an infant food product, a follow-on formula, or a food product for elderly people.
  • nutraceuticals generally encompass foods or food products that provide health and medical benefits. Nutraceuticals are edible and may be eaten directly by humans, but are preferably provided to humans in the form of additives or nutritional supplements, e.g., in the form of tablets or capsules of the kind sold in health food stores.
  • a nutraceutical product is provided, typically a product in the form of a tablet or a capsule, comprising the yeast beta glucan and/or starch as defined herein.
  • the product is provided in the form of a sachet containing a powder comprising the yeast beta glucan and/or starch.
  • such products are provided in unit dose form, i.e. in a form wherein each tablet, capsule or powder sachet contains a unit dose, as defined herein elsewhere.
  • dietetic food product refers to products intended to satisfy particular nutritional requirements of specific groups of the population. This category of products has gained a lot of interest over the past decades, with the Slim-fast and Modifast product lines representing very well- known examples.
  • dietetic food products typically are presented in the form of snacks and meal- replacement products, wherein the consumption of such products instead of regular snacks and meals will provide certain dietary benefits, such as reduced caloric intake and/or increased intake of beneficial dietary components.
  • the most well-known and popular examples of such dietetic food products include the snack bar type product and liquid meal-replacement products. Other examples include ready-meals, savoury snacks, bakery products and dessert-type products.
  • a preferred embodiment of the invention concerns a dietetic food product comprising the present yeast beta glucans, the present starch, the present yeast cell walls and/or the present composition comprising yeast beta glucans.
  • the dietetic food product is a product selected from the group consisting of bars, such as nutritional bars, energy bars, snack bars, cereal bars, bars for diabetics etc.; liquid products, such as nutritional drinks, diet drinks, liquid meal-replacers, sports drinks and other fortified beverages; dessert-type products, such as puddings, yoghurts; savoury snacks, such as chips/ tortillas, puffed and baked snacks, crackers, pretzels, savoury biscuits; and bakery products, such as muffins, cakes, biscuits and pasta, spaghetti.
  • the amount of the yeast beta glucan and/or starch contained in a dietetic food product depends on the kind of food product, in particular its size and composition, as well as on the frequency and amount in which the product is or is supposed to be consumed.
  • the dietetic food product is presented in the form of individually packaged single servings, wherein each serving contains at least 10 % of the amount of the average daily amount of the yeast beta glucan and/or starch as defined herein elsewhere, more preferably at least 25 % or at least 50 % of said average daily amount, more preferably 10 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or 100 % of said average daily amount.
  • the dietetic food product is presented in the form of individually packaged single servings, wherein each serving contains a unit dose as defined herein elsewhere.
  • the amount of the yeast beta glucan in one serving is at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g or at least 10 g.
  • the amount of the yeast beta glucan in one serving is less than 25 g, less than 20 g, less than 15 g, less than 12.5 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g, less than 6 g or less than 5 g.
  • the amount of the resistant starch in one serving is at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g or at least 10 g.
  • the amount of the resistant starch in one serving is less than 25 g, less than 20 g, less than 15 g, less than 12.5 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g, less than 6 g or less than 5 g.
  • the yeast beta glucan is present in an amount of at least 0.1 wt.%, based on the total dry weight of the dietetic food product, more preferably at least 0.25 wt.%, at least 0.5 wt.%, at least 0.75 wt.%, at least 1 wt.%, at least 1.25 wt.%, at least 1.5 wt.%, at least 1.75 wt.%, at least 2 wt.%, at least 2.25 wt.% or at least 2.5 wt.%.
  • the yeast beta glucan is present in an amount of less than 20 wt.%, based on the total dry weight of the dietetic food product, more preferably at less than 10 wt.%, less than 9 wt.%, less than 8 wt.%, less than 7.5 wt.%, less than 7 wt.%, less than 6.5 wt.%, less than 6 wt.%, less than 5.5 wt.%, or less than 5 wt.%.
  • the starch, or resistant starch, as defined herein is present in an amount of at least 0.1 wt.%, based on the total dry weight of the dietetic food product, more preferably at least 0.25 wt.%, at least 0.5 wt.%, at least 0.75 wt.%, at least 1 wt.%, at least 1.25 wt.%, at least 1.5 wt.%, at least 1.75 wt.%, at least 2 wt.%, at least 2.25 wt.% or at least 2.5 wt.%.
  • the starch or resistant starch is present in an amount of less than 20 wt.%, based on the total dry weight of the dietetic food product, more preferably at less than 10 wt.%, less than 9 wt.%, less than 8 wt.%, less than 7.5 wt.%, less than 7 wt.%, less than 6.5 wt.%, less than 6 wt.%, less than 5.5 wt.%, or less than 5 wt.%.
  • the dietetic food product comprises the present yeast beta glucans and present resistant starch in a ratio of (w/w) within the range of 1/5 to 10/1 , preferably 1/2 to 5/1 , more preferably 1/1 to 2/1.
  • a particularly preferred dietetic food product in accordance with the invention is a product in the form of an edible bar, such as a nutritional bar, energy bar, diet bar or food supplement bar, snack bar, etc., examples of which are well known to those of skill in the art.
  • such bars comprise binding syrup including for example glucose syrup, granulated sugar, inulin, oligofructose, glycerol, water, emulsifier, fat, flavors, and cereal components such as oat flakes, raisins and rice crisp, and yeast beta glucan and/or starch.
  • binding syrup including for example glucose syrup, granulated sugar, inulin, oligofructose, glycerol, water, emulsifier, fat, flavors, and cereal components such as oat flakes, raisins and rice crisp, and yeast beta glucan and/or starch.
  • the binding syrup may be heated along with the yeast beta glucan and/or starch with cereal components may be added once the syrup is cooled.
  • the present invention relates to a method for increasing the acetate concentration in the colon of a patient comprising the step of treating overweightness or obesity of a patient by administering an effective amount of a yeast beta glucan or an effective amount of yeast cell walls.
  • the present patient suffers from insufficient acetate concentration in the colon.
  • the present invention relates to a method of treating or preventing overweightness or obesity of a patient, preferably by administering an effective amount of a yeast beta glucan or an effective amount of yeast cell walls or composition comprising yeast beta glucans.
  • the method further comprises the step of diagnosing a patient with insufficient acetate concentration in the colon.
  • the present effective amount is effective to increase the acetate concentration of the patient’s colon.
  • the colon is the distal colon.
  • the patient is overweight or obese. More preferably, the patient is aged 30 to 65 years.
  • the present method further comprises the step of diagnosing a patient as overweight or obese.
  • the patient has a plasma glucose of from 6.1 to 7 mmol/L. More preferably, the patient has a plasma glucose of from 7.0 to 1 1.0 mmol/L.
  • the method comprises administering a dose of yeast beta glucans of from 0.1 to 10 grams per 14 days. More preferably, the present effective amount of yeast beta glucan is a daily amount of at least 0.01g, at least 0.1 g, at least 1 g, at least 2.5 g, at least 5 g, at least 6 g, at least 7 g, at least 8 g, at least 9 g or at least 10 g.
  • the present effective amount is a daily amount of yeast beta glucan of less than 25 g, less than 20 g, less than 15 g, less than 12.5 g, less than 10 g, less than 9 g, less than 8 g, less than 7 g, less than 6 g or less than 5 g.
  • the present effective amount of yeast beta glucan is a daily amount within the range of 0.01 to 25 gam, 1 to 20 gram, 2.5 to 15 gram, 5 to 12.5 gram, 6 to 10 gram or 7 to 9 gram.
  • the invention provides a method of treating and/or preventing a condition or pathology, typically a method of treating or preventing obesity and/or one or more disorders or symptoms associated therewith, in a subject in need thereof, said method comprising administering to said human or animal patient the present yeast beta glucan and resistant starch, or a product comprising the yeast beta glucan and resistant starch as defined herein.
  • the in vitro fermentation model of the colon, TIM-2 was inoculated with pooled fecal microbiota (basically as described in Kortman GA, Dutilh BE, Maathuis AJ, Engelke UF, Boekhorst J, Keegan KP, Nielsen FG, Betley J, Weir JC, Kingsbury Z, Kluijtmans LA, Swinkels DW, Venema K, Tjalsma H. Front Microbiol. 2016, 6:1481 ) samples from 14 obese, prediabetic subjects as well as from 1 1‘metabolically healthy’ subjects.
  • the fecal microbiota was freshly sampled in and directly (within 2h) on ice and under anaerobic conditions. Next, in an anaerobic cabinet, samples were diluted 1 : 1 with dialysate, and pooled at approximately equal weight, after which glycerol was added and aliquots (30 ml/tube) were snap- frozen in liquid nitrogen.
  • the 4x 30-ml aliquots were taken from the -80 freezer and thawed in a water bath at 37°C for exactly 1 hour.
  • the microbiota from the 4 tubes were combined in 1 beaker, the same volume of pre-reduced dialysate was added, and from there divided over 4 syringes of 60 ml with each ca. 60 ml of microbiota-containing liquid.
  • the syringes were sealed with a small flexible tube with a yellow scissor.
  • Each TIM-2 unit was inoculated with 1 of the 4 syringes (i.e. 60 ml microbiota/d ialysate mixture).
  • the yeast cell walls (YCW) (7.5 g of YCW or 7.5 g of YCW + 7.5 g of RS) were added through the sample port, after a 40-hour adaptation period.
  • An experimental week contained the following steps:
  • SIEM Simulated ileal environment medium
  • the fibers tested were: YCW, with and without RS2 (tapioca starch).
  • the study was a double blind, randomized crossover study, which allowed evaluation of the role of mixtures of indigestible carbohydrates on fecal and plasma acetate concentrations and substrate and energy metabolism in 24 male subjects. After initial screening, the subjects obtained their intervention supplement 3 times with at least 14-days washout in between. The day before each visit, participants consumed one of the supplements with standardized meals.
  • the intervention study was set-up as follows. The day before each visit, participants consume one of the supplements with standardized meals:
  • Subjects consumed the supplements with breakfast, lunch and a standardized diner by transferring the content of the sachets in a 150 ml yoghurt and consume the complete yoghurt.
  • Inflammatory markers TNF-a, IL-6, I L- 1 b , Adipokines
  • VAS Visual Analog Scales
  • GSRS Gastrointestinal Symptom Rating Scale
  • the subjects had a 10-hour fasting period.
  • plasma acetate concentration and markers of substrate and energy metabolism was determined.
  • energy expenditure, fat and carbohydrate oxidation (open-circuit ventilated-hood system) was assessed, venous blood was taken, H2 breath and VAS scores were assessed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP19709893.2A 2018-03-08 2019-03-07 Beta-glucane aus hefe Withdrawn EP3761995A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18160628 2018-03-08
PCT/EP2019/055631 WO2019170790A1 (en) 2018-03-08 2019-03-07 Yeast beta glucans

Publications (1)

Publication Number Publication Date
EP3761995A1 true EP3761995A1 (de) 2021-01-13

Family

ID=61599011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19709893.2A Withdrawn EP3761995A1 (de) 2018-03-08 2019-03-07 Beta-glucane aus hefe

Country Status (2)

Country Link
EP (1) EP3761995A1 (de)
WO (1) WO2019170790A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202016488D0 (en) * 2020-10-16 2020-12-02 Univ Dublin Treatment or prevention of hepatic metabolic conditions associated with diabetes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962094A (en) * 1988-10-28 1990-10-09 Alpha Beta Technology, Inc. Glucan dietary additives
FR2919187B1 (fr) * 2007-07-25 2009-11-27 Lesaffre & Cie Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.

Also Published As

Publication number Publication date
WO2019170790A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
Campos-Perez et al. Effects of short chain fatty acids on metabolic and inflammatory processes in human health
US7067498B2 (en) Polymer controlled induced viscosity fiber system and uses thereof
EP2323669B1 (de) Arabinoxylan zur modulation der barrierefunktion der darmoberfläche
KR102149348B1 (ko) 샤도네이씨 생성물을 포함하는 약학적 조성물
EP3263118B1 (de) Leinsamen zur kontrolle des körpergewichtes
Alvarado-Jasso et al. Prebiotic effects of a mixture of agavins and green banana flour in a mouse model of obesity
Harris An introductory review of resistant starch type 2 from high-amylose cereal grains and its effect on glucose and insulin homeostasis
Wen et al. Resistant starches and gut microbiota
EP1878738A1 (de) Allergieunterdrückende zusammensetzung, allergieunterdrückendes nahrungsmittel und allergieunterdrückendes mittel
Sivieri et al. Insights on β-glucan as a prebiotic coadjuvant in the treatment of diabetes mellitus: A review
EP3976051A1 (de) Zusammensetzungen mit 2 -fucosyllactose und gos
EP2635130B1 (de) Zusammensetzung aus gereinigten löslichen mannanen für nahrungsergänzungsmittel und verwendungsverfahren dafür
US7053066B2 (en) Food composition and weight loss method for treating obesity
CN114599232A (zh) 用于预防哮喘的包含2’-岩藻糖基乳糖的组合物
EP3761995A1 (de) Beta-glucane aus hefe
WO2010140182A1 (en) Food compositions comprising flour, glucomannan and a mixture of soluble prebiotic fibres and process for the preparation thereof
Dieny et al. Body Mass Index is The Most Associated Anthropometry Indicators of Obesity with Insulin Resistance in Female College Students
Hasbay Dietary fiber and nutrition
US20210023123A1 (en) Dietary fiber compositions for curative or prophylactic treatment of obesity and other conditions
US20230189864A1 (en) Non-therapeutic methods for maintaining a healthy body weight or losing body weight
JP2010013395A (ja) メタボリックシンドローム症状の予防又は改善剤
AU2003249773C1 (en) Method of lowering glycaemic index of foods
Duar Adaptation and Validation of Food Product Specific Analytical Methods for Monitoring Prebiotics Present in Different Types of Processed Food Matrices
Lyon Dietary Fiber
Lyon Dietary CHAPTER 52 Fiber

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240515